CytoMed Therapeutics (GDTC) Convertible Debt (2022 - 2023)
CytoMed Therapeutics (GDTC) posted Convertible Debt of $25753.0 for Q2 2023, down 99.24% sequentially from $3.4 million in Q4 2022.
CytoMed Therapeutics (GDTC) Convertible Debt (2022 - 2023) Analysis & Trends
CytoMed Therapeutics has reported Convertible Debt for 2 years, with the latest figure at $25753.0 in Q2 2023.
- Quarterly Convertible Debt changed N/A year-over-year to $25753.0 in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $25753.0 (changed N/A YoY) and the FY2022 annual result came in at $3.4 million, changed N/A from the prior year.
- Convertible Debt slipped to $25753.0 in Q2 2023 per GDTC's latest filing, from $3.4 million in the prior quarter.
- Over five years, Convertible Debt peaked at $3.4 million in Q4 2022 and troughed at $25753.0 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.95 Bn | 132.10 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.71 Bn | 78.72 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.71 Bn | 60.52 Bn | 1.37 Bn |
| 4 | Moderna | 60.45 Bn | 55.31 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.24 Bn | 37.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.64 Bn | 10.25 Bn | 668.28 Mn |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - |
| 10 | CytoMed Therapeutics | 9.97 Mn | 8.35 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 25,753.00 |
| Dec 31, 2022 | 3.40 Mn |